Abstract
Objective This study evaluated the legibility, comprehension, and clinical usability of visual timelines for communicating cancer treatment paths. We examined how these visual aids enhance participants and patient understanding of their treatment plans.
Materials and Methods The study included two online surveys and one in-person survey with hematology cancer patients. The online surveys involved 306 and 160 participants respectively, while the clinical evaluation included 30 patients (11 re-surveyed) and 24 medical doctors. Participants were assessed on their ability to understand treatment paths provided with audio information alone or with visual aids. The study also evaluated the comprehension of key treatment terms and the ability of patients to recall their cancer treatment paths.
Results Visual representations effectively communicated treatment terms, with 7 out of 8 terms achieving over 85% transparency as pictograms, compared to 5 out of 8 for comics and 4 out of 8 for photos. Visual treatment timelines improved response quality, increased confidence, and were rated higher in information quality than audio-only information. In the clinical evaluation, patients showed good comprehension (mean response quality: 0.82) and recall (mean response quality: 0.71 after several weeks), and both patients and physicians found the visual aids helpful.
Discussion We discuss that visual timelines enhance patient comprehension and confidence in cancer communication. We also discuss limitations of the online surveys and clinical evaluation. The importance of accessible visual aids in patient consultations is emphasized, with potential benefits for diverse patient populations.
Conclusion Visual aids in the form of treatment timelines improve the legibility and comprehension of cancer treatment paths. Both patients and physicians support integrating these tools into cancer treatment communication.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The following fundings supported this study: HKJ received a salary from a habilitation award of the Medical Faculty of the Technische Universitaet Dresden. HKJ and MB received project funding from the Hochschulstiftung Medizin Dresden. MB received funding from the MSNZ program of the Deutsche Krebshilfe. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The clinical evaluation, including the patients consent form, was approved by the TU Dresden ethics board (BO-EK-338072022).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
To improve clarity we have improved figures, tables, expanded the methods, changed the title, abstract and included further references.
